Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 12.06 9.24% 1.02
KALV closed up 9.24 percent on Thursday, October 17, 2019, on 1.11 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical KALV trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Wide Bands Range Expansion 9.24%
Wide Bands Range Expansion 12.29%
MACD Bullish Signal Line Cross Bullish 12.71%
Wide Bands Range Expansion 12.71%
Shooting Star Candlestick Bearish 9.64%
1,2,3 Retracement Bearish Bearish Swing Setup 9.64%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 9.64%

Older signals for KALV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Medical Specialties Pharmaceutical Diseases Organ Systems Enzymes Diabetic Macular Edema Hereditary Angioedema Angioedema Protease Inhibitor
Is KALV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.92
52 Week Low 9.86
Average Volume 122,564
200-Day Moving Average 19.7844
50-Day Moving Average 14.0206
20-Day Moving Average 11.582
10-Day Moving Average 10.886
Average True Range 0.7724
ADX 37.72
+DI 23.2431
-DI 25.2783
Chandelier Exit (Long, 3 ATRs ) 12.4128
Chandelier Exit (Short, 3 ATRs ) 12.177199999999999
Upper Bollinger Band 13.5195
Lower Bollinger Band 9.6445
Percent B (%b) 0.62
BandWidth 33.457089
MACD Line -0.9164
MACD Signal Line -1.1056
MACD Histogram 0.1892
Fundamentals Value
Market Cap 117.14 Million
Num Shares 9.71 Million
EPS -3.07
Price-to-Earnings (P/E) Ratio -3.93
Price-to-Sales 202.03
Price-to-Book 4.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.76
Resistance 3 (R3) 13.60 12.88 13.47
Resistance 2 (R2) 12.88 12.45 12.96 13.38
Resistance 1 (R1) 12.47 12.18 12.68 12.63 13.28
Pivot Point 11.75 11.75 11.85 11.83 11.75
Support 1 (S1) 11.34 11.32 11.55 11.50 10.84
Support 2 (S2) 10.62 11.05 10.70 10.74
Support 3 (S3) 10.21 10.62 10.65
Support 4 (S4) 10.37